ArticleAndrology2022
Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study.
Article in Andrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Muscle strength changes and physical activity during gender-affirming hormone therapy: A systematic review.Andrology · 2026Pooled it
- A systematic review of psychosocial functioning changes after gender-affirming hormone therapy among transgender people.Nature human behaviour · 2023Pooled it
- Gender-Affirming Medical Treatment Prevalence, Decision Satisfaction, and Future Need Among Transgender Adults.JAMA network open · 2026Article
- Pharmacological Therapy in Patients With Gender Dysphoria: A Cohort Study in the Lazio Region, Italy.Pharmacoepidemiology and drug safety · 2026Article
- Characteristics of Gender-Diverse Patients With Breast Cancer.JAMA network open · 2026Article
- Changes in temperature perception in transgender persons undergoing gender-affirming hormone therapy.Communications medicine · 2026Article
- Article
- Gender-affirming hormone therapy, quality of life, and the role of oestradiol and testosterone in transgender individuals.Acta neuropsychiatrica · 2025Article
- Gender-Affirmation Surgery in Denmark: A Nationwide Register-Based Cohort Study.Transgender health · 2025Article
- Mental and Physical Health Among Danish Transgender Persons Compared With Cisgender Persons.JAMA network open · 2025Article
- Gender detransition: A critical review of the literature.Actas espanolas de psiquiatria · 2023Article
- Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study.Andrology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGender affirming hormonal treatment (GAHT) is a cornerstone in transgender care. National data are sparse regarding use of hormonal treatment by transgender persons.
aimTo assess use of GAHT in transgender persons.
designNational register-based cohort study in Danish transgender persons followed from 2000 until 2018. The main outcome measure was prescription and purchase of GAHT. Persons with ICD-10 diagnosis code of "gender identity disorder" (CGI-cohort) and persons with legal sex change but without diagnosis (CPR-cohort) were included. In the CGI-cohort, transgender women were defined by prescription of estrogen and/or cyproterone acetate and/or testosterone-5-alpha reductase inhibitors, and transgender men were defined by prescription of testosterone after study inclusion. Discontinuation of GAHT was defined as no purchase of GAHT ≥13 months or shift from feminizing to masculinizing hormone treatment, or vice versa.
resultsThe cohort included 2789 transgender persons (n = 1717, CGI-cohort and n = 1072, CPR-cohort). The median age (interquartile range) at study inclusion was 26.1 (17.7) years for persons assigned male at birth (n = 1447) and 22.5 (10.5) years for persons assigned female at birth (n = 1342). In the CGI-cohort, the event rate for GAHT in transgender women increased from 4.0 (95% confidence interval [CI]: [3.1; 5.2]) events per 100 person in year 2000-2005 to 20.6 (17.8; 23.7) between 2014 and 2018. In transgender men, the event rate of GAHT increased from 4.2 (2.8; 6.2) to 18.8 (16.4; 21.6). The rate of discontinuation of GAHT was 0.06 (95% CI 0.049; 0.071) per person year.
conclusionsThe event rate of GAHT increased during 2000-2018. Our data suggested high adherence to GAHT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.